T1	condition 43 59	seroma formation
T2	intervention 86 104	methylprednisolone
T3	control 504 510	saline
T4	outcome-Measure 916 932	seroma formation
T5	outcome-Measure 967 1010	frequency of side-effects and complications
T6	No-of-participants 1023 1026	212
T7	eligibility 1027 1083	women scheduled for mastectomy for primary breast cancer
T9	intervention-participants 1135 1137	69
T10	outcome 1144 1162	developed a seroma
T8	intervention-value 1115 1131	32 (46 per cent)
T11	control-value 1210 1226	52 (78 per cent)
T12	control-participants 1230 1232	67
T13	outcome 1270 1299	mean cumulative seroma volume
T14	outcome 1099 1113	After M + SLNB
T15	outcome 1513 1527	After M + ALND
T16	outcome 1561 1579	developed a seroma
T17	intervention-value 1607 1609	35
T18	intervention-participants 1613 1615	37
T19	intervention-value 1617 1628	95 per cent
T20	control-value 1642 1644	34
T21	control-participants 1648 1650	36
T22	control-value 1652 1663	94 per cent
T23	outcome 1776 1790	infection rate
